Q-omics provides the consensus-scored PLK1 profile across patient tissues and cancer cell-line models. PLK1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PLK1 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, PLK1 RNA expression shows 24,028 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, HNSC, and LSCC as cancer lineages where PLK1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLK1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLK1 survival associations across molecular data types. PLK1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLK1 RNA expression–survival associations across cancer types. High PLK1 expression shows unfavorable associations in KIRP, ACC, KIRC, MESO, KICH and LIHC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PLK1 RNA expression.
This table summarizes PLK1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PLK1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLK1 shows higher tumor expression in HNSC, LUAD, BLCA, KIRP, COAD and KIRC. The HNSC box plot shows higher PLK1 RNA expression in tumor versus normal tissue (log2 FC = +2.495, t-test p < 0.001).
This table shows molecular features associated with PLK1 in patient tissues and cancer cell lines. In patient samples, PLK1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PLK1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Lymphoma.
